Publicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (22)

2025

  1. Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders

    Journal of Clinical Immunology, Vol. 45, Núm. 1

2024

  1. An Exploratory Approach of Clinically Useful Biomarkers of Cvid by Logistic Regression

    Journal of Clinical Immunology, Vol. 44, Núm. 6

  2. Diagnóstico y tratamiento de los trastornos de la presión intracraneal: Documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología

    Neurologia

  3. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 10-15

2023

  1. Consensus about monoclonal antibodies in migraine of the Headache Study Group of the Madrid Association of Neurology

    Kranion, Vol. 18, Núm. 1, pp. 5-20

  2. Diagnosis and treatment of trigeminal neuralgia: Consensus statement from the Spanish Society of Neurology's Headache Study Group

    Neurologia, Vol. 38, pp. S37-S52

  3. Myeloid-derived suppressor cells as a potential biomarker for recurrent pregnancy loss and recurrent implantation failure: Increased levels of MDSCs in recurrent reproductive failure

    American Journal of Reproductive Immunology, Vol. 90, Núm. 5

  4. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

    Biomedicines, Vol. 11, Núm. 4

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. Stereoelectroencephalography in the preoperative assessment of patients with refractory focal epilepsy: Experience at an epilepsy centre

    Neurologia, Vol. 37, Núm. 5, pp. 334-345

2021

  1. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  2. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

  3. Variable immunodeficiency score upfront analytical link (VISUAL), a proposal for combined prognostic score at diagnosis of common variable immunodeficiency

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice

    Brain Sciences, Vol. 10, Núm. 3

  2. Erratum: A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice. (Brain sci. (2020) 10, 176)

    Brain Sciences

  3. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

  4. Morphometric correlates of anomia in patients with small left temporopolar lesions

    Journal of Neuropsychology, Vol. 14, Núm. 2, pp. 260-282

2019

  1. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417

2008

  1. Utilización de la11C-(+)-α-dihidrotetrabenazina para la evaluación de la inervación dopaminérgica en modelos animales de la enfermedad de Parkinson

    Revista Espanola de Medicina Nuclear, Vol. 27, Núm. 2, pp. 103-111

2004

  1. Modelos experimentales en cefaleas

    Neurologia